Improved outcomes in E2A::HLF positive B-cell acute lymphoblastic leukemia by chimeric antigen receptor T cell therapy and BCL-2 inhibitor

Chin Med J (Engl). 2023 Jun 5;136(11):1382-1384. doi: 10.1097/CM9.0000000000002481.

Authors

Shumin Chen¹, Ye Li¹, Zheng Wang¹, Lin Feng¹, Yueping Jia², Xiaodong Mo¹, Yu Wang¹, Qian Jiang¹, Xiaojun Huang^{1

3}, Yueyun Lai¹

Affiliations

¹ Peking University Institute of Hematology, Peking University People's Hospital, Beijing 100044, China.
² Department of Pediatrics, Peking University People's Hospital, Beijing 100044, China.
³ Research Unit of Key Technique for Diagnosis and Treatments of Hematologic Malignancies, Chinese Academy of Medical Sciences (2019RU029), Beijing 100044, China.

No abstract available

Publication types

Letter

MeSH terms

Cell- and Tissue-Based Therapy
DNA-Binding Proteins / genetics
Humans
Oncogene Proteins, Fusion / genetics
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma*
Proto-Oncogene Proteins c-bcl-2 / genetics
Receptors, Chimeric Antigen* / therapeutic use
Translocation, Genetic

Substances

Receptors, Chimeric Antigen
DNA-Binding Proteins
Proto-Oncogene Proteins c-bcl-2
Oncogene Proteins, Fusion